Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Molecular Partners AG
  6. Summary
    MOLN   CH0256379097

MOLECULAR PARTNERS AG

(MOLN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
23.1(c) 24.4(c) 24.85(c) 23.45(c) 23.15(c) Last
33 930 29 029 30 615 82 396 44 205 Volume
-2.53% +5.63% +1.84% -5.63% -1.28% Change
More quotes
Financials
Sales 2021 67,9 M 75,5 M 75,5 M
Net income 2021 -3,19 M -3,55 M -3,55 M
Net cash position 2021 101 M 112 M 112 M
P/E ratio 2021 -204x
Yield 2021 -
Sales 2022 65,2 M 72,6 M 72,6 M
Net income 2022 -15,2 M -17,0 M -17,0 M
Net cash position 2022 71,6 M 79,6 M 79,6 M
P/E ratio 2022 -46,0x
Yield 2022 -
Capitalization 678 M 753 M 754 M
EV / Sales 2021 8,50x
EV / Sales 2022 9,29x
Nbr of Employees 152
Free-Float 75,1%
More Financials
Company
Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The CompanyÔÇÖs pipeline is structured mainly... 
More about the company
Ratings of Molecular Partners AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about MOLECULAR PARTNERS AG
04:11pMOLECULAR PARTNERSá : Announces First Patient Dosed in COVID-19 NIH-Sponsored AC..
PU
06/09MOLECULAR PARTNERSá : to Launch ADSs Listing in US
MT
06/09MOLECULAR PARTNERSá : Announces Launch of American Depositary Shares (ADS) Offer..
PU
05/27NOVARTISá : to Test COVID-19 Treatment Candidate in Phase 2/3 Study
MT
05/27Novartis, Molecular Partners to start clinical trials of COVID-19 drug
RE
05/27NOVARTISá : Molecular Partners Initiate Clinical Trial For Ensovibep in COVID-19..
MT
05/27PRESS RELEASE : Novartis and Molecular Partners -2-
DJ
05/27PRESS RELEASE : Novartis and Molecular Partners announce start of EMPATHY clinic..
DJ
05/27Novartis and Molecular Partners announce start of EMPATHY clinical trial for ..
DJ
05/06MOLECULAR PARTNERS'á : COVID-19 Antiviral Therapy Ensovibep Proves Effective in ..
MT
05/06MOLECULAR PARTNERSá : rsquo; COVID-19 Antiviral Candidate, Ensovibep, Maintains ..
PU
05/04MOLECULAR PARTNERSá : Q1 Loss Widens to $18 Million
MT
05/04INTERIM MANAGEMENT STATEMENT Q1 2021 : Major Advances in COVID-19 Program, Conti..
PU
04/27PRESS RELEASE : Novartis key growth drivers and -4-
DJ
04/27PRESS RELEASE : Novartis key growth drivers and launches continue momentum in Q1..
DJ
More news
News in other languages on MOLECULAR PARTNERS AG
06/09Molecular Partners beginnt öffentliches Angebot von 3 Mio ADS für US-IPO
06/09Molecular Partners lance son programme d'American depositary shares
06/08Aktien Schweiz: Erneut fester - Schwergewichte halten SMI auf Rekordkurs
05/27Aktien Schweiz Schluss: SMI schliesst nach neuem Höchststand etwas schwächer
05/27Bourse Zurich: le SMI dans le rouge après avoir franchi la barre des 11'400 p..
More news
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 31,00 CHF
Last Close Price 23,15 CHF
Spread / Highest target 116%
Spread / Average Target 33,9%
Spread / Lowest Target -4,97%
EPS Revisions
Managers and Directors
NameTitle
Patrick Amstutz Chief Executive Officer & Director
Andreas Emmenegger Chief Financial Officer
William Matt Burns Chairman
Daniel Steiner Senior Vice President-Research
Nicolas Leupin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MOLECULAR PARTNERS AG11.57%753
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966